(MedPage Today) — Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early symptomatic Alzheimer’s disease, a secondary analysis of trial data showed.
In phase II and III trials of…
Source link : https://www.medpagetoday.com/neurology/alzheimersdisease/114601
Author :
Publish date : 2025-03-11 19:03:00
Copyright for syndicated content belongs to the linked Source.
